Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
NextCure Inc
NASDAQ NXTC
Data sourced from
and
and
NextCure Inc Book Value Per Share 3 year CAGR for the quarter ending March 31, 2024: -29.47%
NextCure Inc Book Value Per Share 3 year CAGR is -29.47% for the quarter ending March 31, 2024, a -39.64% change year over year. The book value per share represents the net value of a company allocated to each outstanding share of common stock. It is calculated by dividing shareholders' equity by the weighted average number of shares outstanding. The book value per share provides insight into the intrinsic value of a company's shares and can be used to assess the relative value of a stock compared to its market price. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
NextCure Inc Book Value Per Share for the quarter ending March 31, 2023 was 5.55, a -28.09% change year over year.
-
NextCure Inc Book Value Per Share for the quarter ending March 31, 2022 was 7.72, a -23.67% change year over year.
-
NextCure Inc Book Value Per Share for the quarter ending March 31, 2021 was 10.12, a -10.51% change year over year.
-
NextCure Inc Book Value Per Share for the quarter ending March 31, 2020 was 11.30, a 570.40% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: NXTC
| CEO | Mr. Michael S. Richman MSBA |
| IPO Date | May 9, 2019 |
| Location | United States |
| Headquarters | 9000 Virginia Manor Road, Beltsville, MD, United States, 20705 |
| Employees | 82 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Key trends
StockViz Staff
September 20, 2024
Any question? Send us an email